

- a western blot image in Figure 1G of *EMBO Rep.* Second Submission by manipulating a part of the source image to falsely represent an increase in myosin heavy chain expression in differentiation medium.

- immunofluorescent microscopy images in Figure 2A of *EMBO Rep.* First Submission and Figure 4A of NIH grant application R01 AR070845–01A1 by manipulating parts of the source images to falsely represent the absence of NO66 and Pax7 co-expression in Pax7+ cells.

- western blot images in Figure 5A of *EMBO Rep.* First Submission, Figure Expanded View (EV) 5C of *EMBO Rep.* Second Submission, Figure 8A of NIH grant application R01 DK037175–32, Figure 7A of NIH grant application R01 DK116886–01, and Figure 11A of NIH grant application R01 AR070845–01A1 by manipulating parts of the source images to falsely represent: (1) a lack of expression of retinoblastoma binding protein 4 in the IgG sample, and (2) a positive expression of histone deacetylase 2 in the sample treated with anti-HA antibody.

- Figure 2G of *EMBO Rep.* First Submission, Figures 2H, 6E, and 7C of *EMBO Rep.* Second Submission, Figure 3G of *Cell Rep.* Submission, Figure 3D of NIH grant application R01 AR069533–01A1, and Figure 8C of NIH grant application R01 AR070845–01A1 by reusing and relabeling western blot images to falsely represent both myogenin and GAPDH expression as follows:

- An image of bands representing GAPDH expression was reused and relabeled in: Figure 2G (second row) of *EMBO Rep.* First Submission, Figure 2H (second row) of *EMBO Rep.* Second Submission, Figure 3G (third row) of *Cell Rep.* Submission, Figure 3D (second row) of R01 AR069533–01A1, and Figure 8C (second row) of R01 AR070845–01A1 to represent myogenin expression

- An image of bands representing IGF1R expression was reused and relabeled in: Figure 6E (second row) and Figure 7C (second row) of *EMBO Rep.* Second Submission to represent GAPDH expression

- Figure 4A of *EMBO Rep.* First Submission, Figure 6A of *EMBO Rep.* Second Submission, Figure 5A of *Cell Rep.* Submission, Figure 7A of NIH grant application R01 AR069533–01A1, Figure 10A of NIH grant application R01 AR070845–01A1, and Figure 7A of NIH grant application R01 DK037175–32 by reusing and relabeling one western blot image to falsely represent the results of two replicated experiments.

- Figures 4B and 5B of *EMBO Rep.* First Submission, Figure 6B of *EMBO Rep.* Second Submission, Figure 5C of *Cell Rep.* Submission, Figure 7B of NIH grant application R01 DK116886–01, Figures 7B and 8B of NIH grant application R01 DK037175–32, Figures 10B and 11B of NIH grant application R01 AR070845–01A1, and Figure 7B of NIH grant application R01 AR069533–01A1 by reusing and relabeling three sets of bands from the same source western blot images to falsely represent the expression of different proteins as follows:

- An image of a band was reused and relabeled in:

- Figure 5B (second band in first row) of *EMBO Rep.* First Submission, Figure 7B (second band in first row) of R01 DK116886–01, Figure 8B (second band in first row) of R01 DK037175–32, and Figure 11B (second band in first row) of R01 AR070845–01A1 to represent GAL4.

- Figure 4B (third band in first row) of *EMBO Rep.* First Submission, Figure 5C (third band in first row) of *Cell Rep.* Submission, Figure 6B (third band in first row) of *EMBO Rep.* Second Submission, Figure 7B (third band in first row) of R01 DK037175–32, Figure 10B (third band in first row) of R01 AR070845–01A1, and Figure 7B (third band in first row) of R01 AR069533–01A1 to represent MHC.

- An image of another band was reused and relabeled in:

- Figure 5B (second band in second row) of *EMBO Rep.* First Submission, Figure 7B (second band in second row) of R01 DK116886–01, Figure 8B (second band in second row) of R01 DK037175–32, and Figure 11B (second band in second row) of R01 AR070845–01A1 to represent NO66.

- Figure 4B (third band in third row) of *EMBO Rep.* First Submission, Figure 5C (third band in third row) of *Cell Rep.* Submission, Figure 6B (third band in third row) of *EMBO Rep.* Second Submission, Figure 7B (third band in third row) of R01 DK037175–32, Figure 10B (third band in third row) of R01 AR070845–01A1, and Figure 7B (third band in second row) of R01 AR069533–01A1 to represent myogenin.

- An image of two other bands was reused and relabeled in:

- Figure 5B (first and second bands in bottom row) of *EMBO Rep.* First Submission, Figure 7B (first and second bands in bottom row) of R01 DK116886–01, Figure 8B (first and second bands in bottom row) of R01 DK037175–32, and Figure 11B (first and second bands in bottom row) of R01 AR070845–01A1 to represent H3.

- Figure 4B (first and second bands in bottom row) of *EMBO Rep.* First Submission, Figure 5C (first and second bands in bottom row) of *Cell Rep.* Submission, Figure 6B (first and second bands in bottom row) of *EMBO Rep.* Second Submission, Figure 7B (first and second bands in bottom row) of R01 DK037175–32, Figure 10B (first and second bands in bottom row) of R01 AR070845–01A1 to represent GAPDH, and Figure 7B (first and second bands in bottom row) of R01 AR069533–01A1 to represent GAPDH.

On December 6, 2024, based on the information in the administrative record, the HHS SDO proposed a two-year period of debarment under 2 CFR 180.800(d)—“Any other cause that is so serious or compelling in nature that it affects your present responsibility” to protect the Federal Government’s interest. HHS provided Respondent the opportunity to contest the proposed debarment under 42 CFR part 93 by requesting a hearing before an administrative law judge with the HHS Departmental Appeals Board or alternatively, in lieu of requesting a hearing, to contest under 2 CFR part 180. Respondent did not contest within the prescribed 30-day notice period. Accordingly, the following administrative actions have been implemented:

(1) For a period of two (2) years, beginning on January 16, 2025, Respondent is debarred from participating in “covered transactions” as defined in 42 CFR 180.200 and procurement transactions covered under the Federal Acquisition Regulation (48 CFR chapter 1).

(2) For a period of two (2) years, beginning on January 7, 2025, Respondent is prohibited from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

Dated: March 13, 2025.

Sheila R. Garrity,
Director, Office of Research Integrity, Office of the Assistant Secretary for Health.

[FR Doc. 2025–04489 Filed 3–18–25; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Special Topics in Biodata Management and Analysis.
Date: April 15, 2025.

Time: 9:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Christopher Ryan Mahone, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Room 710F, Bethesda, MD 20892, (443) 224-3992, mahonecr@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Myalgic Encephalomyelitis-Chronic Fatigue Syndrome.

Date: April 21, 2025.

Time: 12:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Simon Peter Peron, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Room 1009K, Bethesda, MD 20892, (301) 594-6236, peronsp@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Infectious Diseases and Immunology C.

Date: April 28-29, 2025.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Melinda H Krick, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Room 808G, Bethesda, MD 20892, (301) 435-1199, krickmh@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Aging and Neurodegeneration.

Date: April 29-30, 2025.

Time: 9:30 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Kathryn Partlow, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1016D, Bethesda, MD 20892, (301) 594-2138, partlowkc@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Topics in biochemistry and chemical biology.

Date: May 1-2, 2025.

Time: 9:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Prema Chandrasekhar Iyer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-1821, prema.iyer@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Centers for Precision Disease Modeling (U54).

Date: May 6, 2025.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 6188, MSC 7804, Bethesda, MD 20892, 301-435-1267, belangerm@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA-AR-24-007: Heal Initiative-HEAL KIDS.

Date: May 7, 2025.

Time: 9:30 a.m. to 1:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Stephanie Christine Nagle Emmens, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594-6604, nagleemmenssc@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Biology of Aging.

Date: May 23, 2025.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Beverly Ann Doran, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-0597, beverly.baptiste@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 13, 2025.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025-04496 Filed 3-18-25; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Integrative Health; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Complementary and Integrative Health Special Emphasis Panel; NCCIH SBIR/STTR Special Emphasis Panel.

Date: May 1-2, 2025.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Center for Complementary and Integrative Health, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jessica M McKlveen, Ph.D., Scientific Review Officer, Office of Scientific Review, Division of Extramural Activities, NCCIH, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, jessica.mcklveen@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS)